|Printable version||E-mail this to a friend|
How to facilitate development of cancer treatment based on genetically modified T-cells
Watch live broadcast of expert discussion at EMA
A workshop on the scientific and regulatory challenges of innovative cancer immunotherapy medicines based on genetically modified T-cells (white blood cells that normally fight off viruses and bacteria) will take place at the European Medicines Agency (EMA) on Tuesday and Wednesday, 15-16 November 2016.
You can follow a live broadcast of the workshop by clicking on the 'multimedia' tab on the event page.
The workshop, which is organised by the Agency’s Committee for Advanced Therapies(CAT), aims to facilitate dialogue between the CAT and medicine developers from industry and academia on current scientific developments, regulatory requirements for product manufacture and clinical development of these medicines.
Immunotherapy is a type of cancer treatment that mobilises the body's own defence mechanisms to fight the cancer. Immunotherapy medicines have significantly improved the therapeutic landscape for patients with certain cancers, such as lung cancer or melanoma.
T-cell based immunotherapy is an innovative approach where T-cells from a patient’s blood are genetically engineered in a laboratory to allow them to recognise cancer cells through specific receptor proteins. In the body of a patient, these so called Chimeric Antigen Receptor (CAR) T-cells can then identify and destroy cancer cells.
CAR T-cell medicines are being developed and are currently being tested in clinical trialsin a variety of cancers. However, there are still many scientific and regulatory challenges to be overcome before these innovative products can be brought to the market for the benefit of patients.
For more information please see the agenda of the workshop.
Presentations and a video recording of the event will be published after the workshop.
- Committee for Advanced Therapies (CAT) workshop: scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products (15-16/11/2016)
- Committee for Advanced Therapies (CAT)
- Programme of the Committee for Advanced Therapies (CAT) workshop: scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products (08/11/2016)
Latest News from
EU and Germany reach agreement on a fair and non-discriminatory road charging scheme02/12/2016 16:27:00
After years of discussions between the EC and the German authorities, both parties agreed on a solution to put an end to the legal dispute over the planned introduction of a road charge for passenger cars in Germany.
European fund for sustainable development: Council agrees negotiating position02/12/2016 16:10:00
On 1 December 2016, the Permanent Representatives Committee (Coreper) agreed on the Council's negotiating position on the regulation on the European fund for sustainable development (EFSD) and establishing the EFSD guarantee and the EFSD guarantee fund. The text will be presented for adoption to the Council in December 2016.
‘Avalanche’ network dismantled in international cyber operation02/12/2016 15:37:00
After more than four years of investigation, the Public Prosecutor’s Office Verden and the Lüneburg Police (Germany), in close cooperation with the United States Attorney’s Office for the Western District of Pennsylvania, the Department of Justice and the FBI, Eurojust, Europol and global partners, dismantled an international criminal infrastructure platform known as ‘Avalanche’.
EC code of conduct: MEPs call for detailed declarations of interest02/12/2016 15:05:00
The EC should revise its code of conduct for Commissioners, to ensure that their declarations of interests give a complete picture of the financial situation and activities of a Commissioner and his or her family, said MEPs in a non-binding resolution voted on Thursday. The “cooling off” period for ex-Commissioners should be prolonged to 36 months, they added.
EC adopts rules to strengthen regulation of commodities markets02/12/2016 14:15:00
The EC has taken steps to strengthen the regulation of commodities markets & curb price speculation. It also ensures that firms active on these markets are regulated appropriately. The package completes the rulebook of secondary measures under the revised Markets in Financial Instruments Directive, known as MIFID II, and gives market participants time to prepare for its application, as of 3 January 2018.